Brokerages Set NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Target Price at $28.50

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) have been assigned a consensus recommendation of "Buy" from the five analysts that are presently covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $28.50.

NRXP has been the topic of several research analyst reports. Wall Street Zen raised shares of NRx Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. HC Wainwright reissued a "buy" rating and issued a $19.00 price objective on shares of NRx Pharmaceuticals in a research report on Thursday, March 20th. BTIG Research initiated coverage on shares of NRx Pharmaceuticals in a research report on Wednesday, April 2nd. They issued a "buy" rating and a $18.00 price objective on the stock. D. Boral Capital restated a "buy" rating and set a $31.00 target price on shares of NRx Pharmaceuticals in a research report on Friday, June 20th. Finally, Ascendiant Capital Markets lifted their price target on shares of NRx Pharmaceuticals from $45.00 to $46.00 and gave the company a "buy" rating in a research report on Tuesday, April 29th.

Institutional Trading of NRx Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Sassicaia Capital Advisers LLC bought a new position in shares of NRx Pharmaceuticals in the fourth quarter worth about $33,000. Squarepoint Ops LLC bought a new position in shares of NRx Pharmaceuticals in the fourth quarter worth about $56,000. Millennium Management LLC bought a new position in shares of NRx Pharmaceuticals in the fourth quarter worth about $61,000. Anson Funds Management LP raised its holdings in NRx Pharmaceuticals by 30.3% in the 4th quarter. Anson Funds Management LP now owns 185,660 shares of the company's stock valued at $408,000 after buying an additional 43,135 shares during the last quarter. Finally, AdvisorShares Investments LLC raised its holdings in NRx Pharmaceuticals by 138.5% in the 4th quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company's stock valued at $683,000 after buying an additional 180,229 shares during the last quarter. Institutional investors own 4.27% of the company's stock.

NRx Pharmaceuticals Price Performance

Shares of NRx Pharmaceuticals stock traded down $0.06 on Friday, hitting $3.21. The company had a trading volume of 169,264 shares, compared to its average volume of 419,525. NRx Pharmaceuticals has a twelve month low of $1.10 and a twelve month high of $6.01. The stock has a 50-day moving average of $2.90 and a 200-day moving average of $2.65. The firm has a market capitalization of $55.50 million, a P/E ratio of -1.60 and a beta of 1.59.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.06. The business had revenue of $1.14 million for the quarter, compared to analyst estimates of $1.14 million. Equities analysts predict that NRx Pharmaceuticals will post -1.75 EPS for the current year.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.